M
IMEPro
K21.0 Internal Medicine
Updated March 2026

Gastro-esophageal reflux disease with esophagitis

ICD-10 Code: K21.0 · Body Part: Lumbar Spine

QME Evaluation Process

GI evaluation, endoscopy review, symptom severity assessment. Chapter 6 digestive system impairment. May be secondary to medication use for industrial injury.

Typical Impairment Rating

0-10% WPI

AMA Guides Edition

5th Edition

Common Treatments

+ PPI medication
+ H2 blockers
+ Dietary modification
+ Nissen fundoplication for severe cases

Related Conditions

Body Part Guide

Lumbar Spine Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Gastro-esophageal reflux disease with esophagitis

Find a QME Specialist

Browse QME-certified physicians who evaluate gastro-esophageal reflux disease with esophagitis and related lumbar spine conditions in California.

Browse Neurology Physicians →

Frequently Asked Questions

What is Gastro-esophageal reflux disease with esophagitis (K21.0)?

Gastro-esophageal reflux disease with esophagitis is an ICD-10 diagnosis code (K21.0) classified under Internal Medicine conditions. It affects the Lumbar Spine and is occasionally seen in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is K21.0 rated for impairment?

The typical whole person impairment (WPI) range for Gastro-esophageal reflux disease with esophagitis is 0-10% WPI. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for K21.0?

GI evaluation, endoscopy review, symptom severity assessment. Chapter 6 digestive system impairment. May be secondary to medication use for industrial injury.

What treatments are common for Gastro-esophageal reflux disease with esophagitis?

Common treatments for Gastro-esophageal reflux disease with esophagitis include PPI medication, H2 blockers, Dietary modification, Nissen fundoplication for severe cases. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.